Reslizumab

• CAT Number: I017508
• CAS Number: 241473-69-8
• Purity: ≥95%

Reslizumab (CAT: I017508) is a humanized monoclonal antibody that selectively targets interleukin-5 (IL-5), a key cytokine regulating eosinophil growth and survival. By neutralizing IL-5 activity, Reslizumab effectively reduces eosinophilic inflammation, making it a therapeutic agent for eosinophilic asthma and related disorders. It binds human IL-5 with high affinity (Kᴅ = 109 pM by Biacore; 4.3 pM by kinetic exclusion assay) and inhibits IL-5–dependent cell proliferation (IC₅₀ ≈ 91.1 pM). In vivo, Reslizumab dose-dependently suppresses pulmonary eosinophilia and airway hyperresponsiveness in multiple animal models, demonstrating long-lasting efficacy in reducing IL-5–driven respiratory inflammation.